Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Edison Investment Research Limited: Edison issues initiation on Silence Therapeutics (SLN)

9 Jan 2020 10:04

Edison Investment Research Limited Edison Investment Research Limited: Edison issues initiation on Silence Therapeutics (SLN) 09-Jan-2020 / 10:03 GMT/BST


 

London, UK, 9 January 2020

Edison issues initiation on Silence Therapeutics (SLN)

We are initiating coverage of Silence Therapeutics (SLN), a developer of siRNA drugs for diseases that can be genetically targeted. Silence has a proprietary platform for developing siRNA therapeutics, the strength of which was highlighted by preclinical development deals with Mallinckrodt and Takeda (details below). The company will also be re-entering the clinic in Q120 with SLN124, its own drug for iron overload. We are initiating with a valuation of £345m or 440p per share.

 

Our initial valuation of £345m or 440p per share is based on a risk-adjusted NPV analysis of the firm's assets and revenue streams and is driven primarily by our valuation of SLN124 (£141m). We forecast that it will require £105m in additional capital to reach profitability in 2026, offset by potential business development deals.

Click here to view the full report.

 

Subscribe to Edison's content to receive reports by email.

All reports published by Edison are free-to-access and available on the website.

 

About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information please contact Edison:

Nathaniel Calloway, +1 646 653 7036

healthcare@edisongroup.com

 

Learn more at www.edisongroup.com and connect with Edison on:

LinkedIn https://www.linkedin.com/company/edison-group-

Twitter  www.twitter.com/Edison_Inv_Res

YouTube www.youtube.com/edisonitv


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

949913 09-Jan-2020 

corporate announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

Date   Source Headline
10th Aug 20114:41 pmRNSSecond Price Monitoring Extn
10th Aug 20114:35 pmRNSPrice Monitoring Extension
8th Aug 20114:35 pmRNSPrice Monitoring Extension
5th Aug 20114:40 pmRNSSecond Price Monitoring Extn
5th Aug 20114:35 pmRNSPrice Monitoring Extension
3rd Aug 20114:40 pmRNSSecond Price Monitoring Extn
3rd Aug 20114:35 pmRNSPrice Monitoring Extension
3rd Aug 20117:00 amPRNNotice of Allowance for New U.S. Patent
1st Aug 20114:40 pmRNSSecond Price Monitoring Extn
1st Aug 20114:35 pmRNSPrice Monitoring Extension
1st Aug 20117:00 amPRNGroup Reorganisation and Board Changes
18th Jul 20114:40 pmRNSSecond Price Monitoring Extn
18th Jul 20114:35 pmRNSPrice Monitoring Extension
12th Jul 20114:40 pmRNSSecond Price Monitoring Extn
12th Jul 20114:35 pmRNSPrice Monitoring Extension
8th Jul 20114:40 pmRNSSecond Price Monitoring Extn
8th Jul 20114:35 pmRNSPrice Monitoring Extension
6th Jul 20114:41 pmRNSSecond Price Monitoring Extn
6th Jul 20114:35 pmRNSPrice Monitoring Extension
5th Jul 20114:40 pmRNSSecond Price Monitoring Extn
5th Jul 20114:35 pmRNSPrice Monitoring Extension
1st Jul 20114:40 pmRNSSecond Price Monitoring Extn
1st Jul 20114:35 pmRNSPrice Monitoring Extension
30th Jun 20114:40 pmRNSSecond Price Monitoring Extn
30th Jun 20114:35 pmRNSPrice Monitoring Extension
29th Jun 20114:40 pmRNSSecond Price Monitoring Extn
29th Jun 20114:35 pmRNSPrice Monitoring Extension
28th Jun 20114:40 pmRNSSecond Price Monitoring Extn
28th Jun 20114:35 pmRNSPrice Monitoring Extension
23rd Jun 20114:41 pmRNSSecond Price Monitoring Extn
23rd Jun 20114:35 pmRNSPrice Monitoring Extension
17th Jun 20114:40 pmRNSSecond Price Monitoring Extn
17th Jun 20114:35 pmRNSPrice Monitoring Extension
16th Jun 20114:40 pmRNSSecond Price Monitoring Extn
16th Jun 20114:35 pmRNSPrice Monitoring Extension
13th Jun 20113:33 pmPRNResults of Annual General Meeting
9th Jun 20114:40 pmRNSSecond Price Monitoring Extn
9th Jun 20114:35 pmRNSPrice Monitoring Extension
8th Jun 20114:40 pmRNSSecond Price Monitoring Extn
8th Jun 20114:35 pmRNSPrice Monitoring Extension
6th Jun 20112:00 pmPRNPresentation at ASCO
1st Jun 20117:00 amPRNSilence Therapeutics Post-Fundraising Update
25th May 20111:56 pmPRNTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
20th May 20119:26 amPRNTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
19th May 20111:52 pmPRNTR-1: Notification Of Major Interest In Shares
19th May 201110:05 amRNSForm 8.3 - Silence Therapeutics]
19th May 20117:00 amPRNNew Data from Phase I Study with Atu027
19th May 20117:00 amPRNNew Data from Phase I Study with Atu027
18th May 20113:45 pmPRNTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
18th May 20117:00 amPRNPublication of 2010 Annual Report and Notice of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.